In episode 1, Bove explores how ofatumumab, a B-cell–depleting therapy, stands apart from fingolimod and fumarates, and why its mechanism may offer distinct treatment advantages.
CD20-Targeting Therapy Insights: Ofatumumab in Multiple Sclerosis Care
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
N-Acetyl-L-Leucine Reduces Disease Progression in Phase 2 Extension Study for Ataxia-Telangiectasia
2
Phase 2 Controlled Trial Tests Potential of Probiotics in Parkinson-Related Depression, Mood Disorders
3
Mechanism and Rationale of Zorevunersen
4
NeuroVoices: A. Jon Stoessl, MD, on Understanding Plasticity and Disease Trajectory in Parkinson Disease
5
